mAbxience II Biosimilar Forum

To drive scientific exchange on biopharmaceuticals and high-quality treatment options, more than 180 physicians, pharmacists, and hospital managers from around the world came together in a global conference and over 423 attendees via streaming. On October 21, mAbxience, a leading international biopharmaceutical company of which Fresenius Kabi acquired a majority stake, has celebrated its 2nd Biosimilar Forum at Madrid. In a live-streamed event, experts in the field discussed current topics such as the value of biosimilars to the pharmaceutical expenditure, the maximization of biosimilars penetration and the health care providers-to-patient communication relevant to biosimilar adoption.